Skip to content

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-505579-53-00
Acronym
INCMOR 0208-305
Enrollment
74
Registered
2023-11-28
Start date
2022-10-25
Completion date
Unknown
Last updated
2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma (DLBCL)

Brief summary

ORR (overall response rate), defined as the percentage of participants having best response of CR or PR as per IRC assessment.

Detailed description

• DOR (Duration of Response), defined as time from 1st documented CR (complete response) or PR (partial response) until the date of 1st documented disease progression or death due to any cause, whichever occurs first, among participants who achieve CR or PR per IRC (independent review committee) assessment. Refer protocol for complete list.

Interventions

Sponsors

Incyte Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
ORR (overall response rate), defined as the percentage of participants having best response of CR or PR as per IRC assessment.

Secondary

MeasureTime frame
• DOR (Duration of Response), defined as time from 1st documented CR (complete response) or PR (partial response) until the date of 1st documented disease progression or death due to any cause, whichever occurs first, among participants who achieve CR or PR per IRC (independent review committee) assessment. Refer protocol for complete list.

Countries

Bulgaria, Croatia, Czechia, Denmark, Finland, Hungary, Ireland, Norway, Poland, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026